Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786376 | 0.86 | DRD2 (0.47) | MAPTALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL811240 | 0.81 | TSHR (0.38) | MAPTHSD17B10TSHRTDP1DRD2 | |
| SCHEMBL12599868 | 0.79 | CYP1A2 (0.49) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL13709448 | 0.79 | DRD2 (0.37) | MAPTALDH1A1HSD17B10KDM4ECYP2A6 | |
| SCHEMBL19797772 | 0.75 | TMEM97 (0.40) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL682960 | 0.74 | ALDH1A1 (0.55) | MAPTALDH1A1KDM4E | |
| SCHEMBL32082017 | 0.74 | ALDH1A1 (0.55) | MAPTALDH1A1KDM4E | |
| SCHEMBL13317746 | 0.73 | DRD2 (0.34) | MAPTALDH1A1HSD17B10KDM4ECYP2A6 | |
| SCHEMBL12786238 | 0.73 | DRD2 (0.34) | MAPTALDH1A1HSD17B10KDM4ECYP2A6 | |
| SCHEMBL12599382 | 0.72 | MC4R (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-7994355-B2 | Metallocene-based chiral phosphine or arsine ligands | SOLVIAS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7906669-B2 | Metallocene-based phosphorus chiral phosphines | SOLVIAS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | PHOENIX CHEMICALS LTD (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1709054-B1 | METALLOCENE-BASED CHIRAL PHOSPHINE OR ARSINE LIGANDS | PHOENIX CHEMICALS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | PHOENIX CHEMICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080242876-A1 | Process For the Manufacture of Substituted Propionic Acids | PHOENIX CHEMICALS LTD. (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | PHOENIX CHEMICALS LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | OXSR1, OXGR1, OSR1 | MEN1 2434/4885KMT2A 2666/4885MAPT 4731/4885 |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | OSGEP, PHOSPHO1, ITPA | MEN1 119/4885KMT2A 2944/4885MAPT 4021/4885 |
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | POLL, ZNF207, ZC3HAV1L | MEN1 1134/4885KMT2A 1388/4885MAPT 4816/4885 |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | MEN1 1768/4885KMT2A 2638/4885MAPT 326/4885 |
| US-20080242876-A1 | Process For the Manufacture of Substituted Propionic Acids | AS3MT, PPA1, AGPS | MEN1 601/4885KMT2A 1689/4885MAPT 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.